You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Drug Sales Trends for FLOVENT DISK


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for FLOVENT DISK (2022)

Revenues by Pharmacy Type

Pharmacy Type Revenues
INSIDE ANOTHER STORE $14,661,725
DRUG STORE $2,366,479
[disabled in preview] $0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
INSIDE ANOTHER STORE 71,641
DRUG STORE 11,447
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $161,795
MEDICARE $13,417,421
[disabled in preview] $3,448,988
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for FLOVENT DISK
Drug Units Sold Trends for FLOVENT DISK

Annual Sales Revenues and Units Sold for FLOVENT DISK

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
FLOVENT DISK ⤷  Try for Free ⤷  Try for Free 2022
FLOVENT DISK ⤷  Try for Free ⤷  Try for Free 2021
FLOVENT DISK ⤷  Try for Free ⤷  Try for Free 2020
FLOVENT DISK ⤷  Try for Free ⤷  Try for Free 2019
FLOVENT DISK ⤷  Try for Free ⤷  Try for Free 2018
>Drug Name >Revenues (USD) >Units >Year

Market Analysis and Sales Projections for Flovent Diskus

Last updated: December 31, 2024

Overview of Flovent Diskus

Flovent Diskus, manufactured by GlaxoSmithKline (GSK), is an inhaled corticosteroid used as a controller medicine to treat asthma. It is available in various strengths and has been a significant player in the respiratory disease treatment market.

Market Trends and Growth

Global Airway Disease Treatment Market

The global airway disease treatment market, which includes treatments for asthma and COPD, is projected to grow significantly. By 2032, this market is expected to reach a revenue of around $3,495.3 million, up from $1,996.1 million in 2022, with a Compound Annual Growth Rate (CAGR) of 5.2%[3].

Regional Growth

The Asia Pacific region is expected to drive a substantial portion of this growth due to the increasing prevalence of chronic respiratory illnesses and the introduction of effective generic treatments. China and Japan are particularly significant markets, with products like Pulmicort seeing favorable performance in these regions[3].

Sales Performance of Flovent Diskus

Historical Sales

Historically, Flovent Diskus has been a key product in GSK's respiratory portfolio. However, the sales dynamics have been influenced by several factors, including the introduction of authorized generics and changes in market conditions.

Authorized Generics

GSK launched an authorized generic for Flovent HFA in May 2022 and for Flovent Diskus in October 2023. These generics are expected to provide patients with lower-cost alternatives, which could impact the sales of the branded versions. Despite this, the authorized generics are anticipated to maintain a significant market presence due to their affordability and medical importance[4][5].

Discontinuation of Branded Versions

As of January 1, 2024, GSK discontinued the manufacturing of branded Flovent HFA and Flovent Diskus for the US market. This move is part of a broader strategy to adjust to market conditions and the impact of authorized generics[5].

Sales Projections

Short-Term Outlook

For 2024, GSK expects sales in the General Medicines segment, which includes Flovent Diskus, to decrease by mid-single-digit percentages at constant exchange rates (CER). This decline is partly due to the impact of authorized generics and competitive pressure in the US market[2][5].

Long-Term Outlook

Despite the short-term challenges, the long-term outlook for inhaled corticosteroids like Flovent Diskus remains positive. The growing prevalence of asthma and COPD, coupled with the increasing demand for affordable treatments, is expected to sustain the market. However, the exact sales projections for Flovent Diskus will depend on how well the authorized generics perform and how the market responds to these changes[1][3].

Competitive Landscape

Market Competition

The respiratory disease treatment market is highly competitive, with several major players. The introduction of authorized generics for Flovent Diskus adds another layer of competition, as these products are likely to capture a significant portion of the market share. Other products like Pulmicort and new entrants in the market will also influence the sales dynamics of Flovent Diskus[3][5].

Regulatory and Environmental Factors

HFC Propellant Use

Flovent Diskus, like other metered dose inhalers (MDIs), uses hydrofluorocarbons (HFCs) as propellants. The use of HFCs in MDIs accounts for a small percentage of total HFC use but is subject to regulatory scrutiny due to environmental concerns. The EPA estimates that HFC use in MDIs will continue to grow but at a modest rate of about 1% per year through 2025[1].

Patient Affordability and Access

Pricing Adjustments

GSK has made efforts to improve patient affordability by launching authorized generics and adjusting list prices. For instance, the list prices for several GSK products, including Advair and Lamictal, were cut significantly in January 2024. This strategy aims to ensure that patients have access to essential medications at lower costs[5].

Key Takeaways

  • Market Growth: The global airway disease treatment market is expected to grow at a CAGR of 5.2% from 2022 to 2032.
  • Authorized Generics: GSK has launched authorized generics for Flovent HFA and Flovent Diskus, which will impact the sales of branded versions.
  • Discontinuation: Branded Flovent HFA and Flovent Diskus were discontinued in the US market as of January 1, 2024.
  • Competitive Landscape: The market is highly competitive, with significant competition from other inhaled corticosteroids and generics.
  • Regulatory Factors: The use of HFCs in MDIs is subject to regulatory scrutiny, but the impact on Flovent Diskus sales is expected to be minimal.

FAQs

What is Flovent Diskus used for?

Flovent Diskus is an inhaled corticosteroid used as a controller medicine to treat asthma.

Why did GSK discontinue the branded versions of Flovent Diskus?

GSK discontinued the branded versions of Flovent Diskus in the US market as part of a strategy to adjust to market conditions and the impact of authorized generics.

What is the impact of authorized generics on Flovent Diskus sales?

The authorized generics for Flovent Diskus are expected to capture a significant portion of the market share, potentially reducing the sales of the branded versions.

How does the global airway disease treatment market affect Flovent Diskus sales?

The growing global airway disease treatment market, driven by increasing prevalence of chronic respiratory illnesses, supports the long-term demand for products like Flovent Diskus.

What regulatory factors could affect Flovent Diskus sales?

The use of HFCs in MDIs, including Flovent Diskus, is subject to environmental regulations, but this is expected to have a minimal impact on sales through 2025.

Sources

  1. EPA: Market Characterization of the U.S. Metered Dose Inhaler Industry[1].
  2. GSK: Q2 2024 Pre-Announcement Aide Memoire[2].
  3. Future Market Insights: Airway Disease Treatment Market Size, Trend & Outlook - 2032[3].
  4. Asthma and Allergy Foundation of America: Flovent HFA and Flovent Diskus Asthma Medicines Being Discontinued[4].
  5. GSK: Q4 2023 Pre-Announcement Aide Memoire[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.